Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates

Journal of Virological Methods

Volumn 64, Issue 1, 1997, Pages 81-93

  Candotti, Daniel ^a   Rosenheim, Michel ^a   Huraux, Jean Marie ^a   Agut, Henri ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

HIV 1 primary iolates; immune sera; monoclonal antibodies; PCR based neutralization assay; V3 loop

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREACTIVITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; HIV ANTIBODIES; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; SPECIES SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031046678     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(96)02145-3     Document Type: Article

References (56)

1. Akerblom, L., Hinkula, J., Broliden, P.-A. et al. (1990) Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 4, 953-960.
2. Albert, J. and Fenyö, E.M. (1990) Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers. J. Clin. Microbiol. 28, 1560-1564.
3. Albert, J., Abrahamsson, B., Nagy, K. et al. (1990) Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107-112.
4. Alexander, S. and Elder, J.H. (1984) Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science 226, 1328-1330.
5. Barré-Sinoussi, F., Chermann, J.-C., Rey, F. et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871.
6. Berman, P.W., Gregory, T.J., Riddle, L. et al. (1990) Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 345, 622-625.
7. Berman, P.W., Matthews, T.J., Riddle, L. et al. (1992) Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 66, 4464-4469.
8. Broliden, P.-A., von Gegerfelt, A., Clapham, P. et al. (1992) Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. USA 89, 461-465.
9. Candotti, D., Jung, M., Kerouedan, D. et al. (1991) Genetic variability affects the detection of HIV by polymerase chain reaction. AIDS 5, 1003-1007.
10. Candotti, D., Chappey, C., Rosenheim, M., M'Pele, P., Huraux, J.-M. and Agut, H. (1994) High variability of the gag/pol transframe region among HIV-1 isolates. C. R. Acad. Sci. (Paris) 317, 183-189.
11. Cloyd, M.W. and Moore, B.E. (1990) Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates. Virology 174, 103-116.
12. Conley, A.J., Gorny, M.K., Kessler, II J.A. et al. (1994) Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody 447-52D. J. Virol. 68, 6994-7000.
13. Dalgleish, A. and Malkovsky, M. (1988) Advances in human retrovirus. Adv. Cancer Res. 51, 307-360.
14. Emini, E.A., Nara, P.L., Schleif, W.A. et al. (1990) Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virol. 64, 3674-3678.
15. Eron, J.J., Gorczyca, P., Kaplan, J.C. and D'Aquila, R.T. (1992) Susceptibility testing by polymerase chain reaction DNA quantitation: a method to measure drug resistance of human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 89, 3241-3245.
16. Fultz, P.N., Nara, P., Barre-Sinoussi, F. et al. (1992) Vaccine protection of chimpanzees against challenge with HIV-1 infected peripheral blood mononuclear cells. Science 256, 1687-1689.
17. Fung, M.S.C., Sun, C.R.Y., Gordon, W.L. et al. (1992) Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66, 848-856.
18. Girard, M., Kieny, M.-P., Renter, A. et al. (1991) Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88, 542-546.
19. Gorny, M.K., Conley, A.J., Karwowska, S. et al. (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66, 7538-7542.
20. Gorny, M.K., Xu, J.-Y., Karwowska, S., Buchbinder, A. and Zolla-Pazner, S. (1993) Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150, 635-643.
21. Gurgo, C., Guo, H.-G., Franchini, G. et al. (1988) Envelope sequences of two new United States HIV-1 isolates. Virology 164, 531-536.
22. Haigwood, N.L., Shuster, J.R., Moore, G.K. et al. (1990) Importance of hypervariable regions of HIV-1 gp120 in the generation of virus-neutralizing antibodies. AIDS Res. Hum. Retroviruses 6, 855-869.
23. Hansen, J.-E.S., Clausen, H., Nielsen, C. et al. (1990) Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. J. Virol. 64, 2833-2840.
24. Higuchi, R.G. and Ochman, H. (1989) Production of single-stranded DNA templates by exonuclease digestion following the polymerase chain reaction. Nucleic Acids Res. 17, 5865.
25. Hoskins, T.W., Davies, J.R., Smith, A.J., Miller, C.I. and Allchin, A. (1979) Assessment of inactivated influenza-A vaccine after three outbreaks of influenza-A at Christ's hospital. Lancet i, 33-35.
26. Hu, S.-L., Klaniecki, J., Dykers, T., Sridhar, P. and Travis, B.M. (1991) Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160. AIDS Res. Hum. Retroviruses 7, 615-620.
27. Javaherian, K., Langlois, A.J., LaRosa, G.J. et al. (1990) Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250, 1590-1593.
28. Kinney-Thomas, E., Weber, J.N., McClure, J. et al. (1988) Neutralizing monoclonal antibodies to the AIDS virus. AIDS 2, 25-29.
29. Kostrikis, L.G., Cao, Y., Ngai, H., Moore, J.P. and Ho, D.D. (1996) Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70, 445-458.
30. Lennette, E.H. (1992) Laboratory diagnosis of viral infections (second edition) Marcel Dekker, New York.
31. Levy, J.A. (1993) Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57, 183-289.
32. McKnight, A., Clapham, P.R., Goudsmit, J., Cheingsong-Popov, R., Weber, J.N. and Weiss, R.A. (1992) Development of HIV-1 group-specific neutralizing antibodies after seroconversion. AIDS 6, 799-802.
33. McKnight, A., Weiss, R.A., Shotton, C., Takeuchi, Y., Hoshino, H. and Clapham, P.R. (1995) Change in tropism upon immune escape by human immunodeficiency virus. J. Virol. 69, 3167-3170.
34. Milich, L., Margolin, B. and Swanstrom, R. (1993) V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J. Virol. 67, 5623-5634.
35. Moore, J.P., Cao, Y., Qing, L. et al. (1995) Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69, 101-109.
36. Moore, J.P., Trkola, A., Korber, B. et al. (1995) A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside subtype B. J. Virol. 69, 122-130.
37. Myers, G., Korber, B., Wain-Hobson, S., Smith, R.F. and Pavlakis, G.N. (1993) Human retroviruses and AIDS 1993: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory, Theoretical Biology and Biophysics (T10), Los Alamos, N Mex.
38. Nara, P.L., Smit, L., Dunlop, N. et al. (1990) Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J. Virol. 64, 3779-3791.
39. Neumuller, M., Karlsson, A., Lennerstrand, J. et al. (1992) HIV-1 reverse transcriptase inhibiting antibody titer in serum: relation to disease progression and to core-antibody levels. J. Med. Virol. 36, 283-291.
40. Papsidero, L.D., Sheu, M. and Ruscetti, F.W. (1989) Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J. Virol. 63, 267-272.
41. Robert-Guroff, M., Louie, A., Myagkikh, M. et al. (1994) Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization. J. Virol. 68, 3459-3466.
42. Sawyer, L.S.W., Wrin, M.T., Crawford-Miksza, L. et al. (1994) Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68, 1342-1349.
43. Schwander, S., Braum, R.W., Kühn, J.E. et al. (1992) Prevalence of antibodies to recombinant virion infectivity factor in the sera of prospectively studied patients with HIV-1 infection. J. Med. Virol. 36, 142-146.
44. Spira, A.I. and Ho, D.D. (1995) Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro. J. Virol. 69, 422-429.
45. Steimer, K.S., Scandella, C.J., Skiles, P.V. and Haigwood, N.L. (1991) Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254, 105-108.
46. Sullivan, N., Thali, M., Furman, C., Ho, D.D. and Sodroski, J. (1993) Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J. Virol. 67, 3674-3679.
47. Sullivan, N., Sun, Y., Li, J., Hofmann, W. and Sodrowski, J. (1995) Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69, 4413-4422.
48. Tamalet, C., Lafeuillade, A., Yahi, H. et al. (1994) Comparison of viral burden and phenotype of HIV-1 isolates from lymph nodes and blood. AIDS 8, 1083-1088.
49. Thali, M., Moore, J.P., Furman, C. et al. (1993) Characterization of conserved human immunoeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67, 3978-3988.
50. Tremblay, M. and Wainberg, M.A. (1990) Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J. Infect. Dis. 162, 735-737.
51. Turner, S., Tizard, R., DeMarrinis, J. et al. (1992) Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 89, 1335-1339.
52. VanCott, T.C., Polonis, V.R., Loomis, L.D. et al. (1995) Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses 11, 1379-1391.
53. Werner, A. and Levy, J.A. (1993) Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4. J. Virol. 67, 2566-2574.
54. Wrin, T., Loh, T.P., Vennari, J.C., Schuitemaker, H. and Nunberg, J.H. (1995) Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69, 39-48.
55. Zolla-Pazner, S. and Gorny, M.K. (1992) Passive immunization for the prevention and treatment of HIV infection. AIDS 6, 1235-1247.
56. Zolla-Pazner, S. and Sharpe, S. (1995) A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res. Hum. Retroviruses 11, 1449-1458.